Hi there,

Can you donate $10 per month to support Democracy Now!’s independent journalism all year long? Since our very first broadcast in 1996, we’ve refused to take government or corporate funding, because nothing is more important to us than our editorial independence. When Democracy Now! covers war and peace or the climate crisis, we’re not brought to you by the weapons manufacturers or the oil, gas, coal or nuclear companies. When we cover healthcare, we’re not brought to you by the insurance industry or Big Pharma. Our journalism is powered by YOU. But that means we can’t do our work without you.Right now, a generous donor will DOUBLE your gift, which means your $10 donation this month will be worth $20 to Democracy Now! Please do your part today. Every dollar counts. Thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


Pfizer Asks for FDA Approval of Omicron-Specific Booster Shot

HeadlineAug 23, 2022

Pfizer and BioNTech have asked the FDA to approve a new version of its COVID-19 vaccine that targets mutated forms of the coronavirus. Pfizer’s updated shot is based on both the original virus that first emerged in 2019, as well as the BA.4 and BA.5 Omicron subvariants that now account for nearly all U.S. cases. Pfizer submitted its application without completing a new clinical trial, meaning it’s not clear whether the updated vaccine will provide more protection. mRNA vaccines produced by Pfizer and Moderna remain highly effective at preventing severe disease and death from COVID but are much less effective at preventing infection and mild disease.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation